Enterprise Value
42.79M
Cash
9.622M
Avg Qtr Burn
-10.41M
Short % of Float
13.55%
Insider Ownership
0.79%
Institutional Own.
11.44%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Fasedienol (PH94B) Details Social Anxiety Disorder | Phase 3 Initiation | |
Itruvone, PH10 (pherine nasal spray ) Details Major depressive disorder | Phase 2b Initiation | |
PH94B (pherine nasal spray) (fasedienol) Details Adjustment Disorder | Phase 2a Update | |
PH80 ( nasal spray ) Details Menopause, Hot flashes | Phase 2a Update | |
AV-101(4-Cl-KYN) (targets the NMDAR) Details Major depressive disorder | Phase 1b Update |